Abstract: The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.

Abstract: The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.

Abstract: The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.

Abstract: The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.

Abstract: The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.

Abstract: The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.

Abstract: The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.

Abstract: The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.

Abstract: The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.

Abstract: The present invention relates to certain resorcinol derivatives and their use as skin lightening agents.

Abstract: The present invention provides a compound in substantially pure form having the structure: ##STR1## wherein each of R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, and R.sub.8 may independently be hydrogen, halogen, nitro, CF.sub.3, hydroxy, C.sub.1-5 alkyl, aryl or OR.sub.9, wherein R.sub.9 is C.sub.1-5 alkyl, wherein R.sub.10 is COC.sub.1-5 alkyl; or wherein any two consecutive R groups may be members of a C.sub.5 -C.sub.6 membered ring, and wherein the intracyclic-dashed line represents a covalent bond which may be present or absent, with the proviso that when R.sub.10 is present, the exocyclic-covalent bond is absent, and when R.sub.10 is absent, the exocyclic-covalent bond is present, and with the proviso that when R.sub.10 is absent, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, and R.sub.8 cannot all be hydrogen and when R.sub.10 is absent, R.sub.5, R.sub.6, R.sub.7, and R.sub.8 cannot all be hydrogen when either R.sub.1, R.sub.2, R.sub.3, or R.sub.

Abstract: The invention relates to salts formed between ranitidine and a complex of zinc with a carboxylic acid selected from tartaric acid, citric acid and alkyl citric acids, and to solvates of such salts. The salts and solvates thereof are useful in the treatment of gastro-intestinal disorders, such as peptic ulcer disease and non-ulcer dyspepsia.

Abstract: The invention relates to a salt of a basic histamine H.sub.2 -receptor antagonist of formula (I) ##STR1## and a complex of bismuth with a carboxylic acid selected from tartaric acid, citric acid and alkyl citric acids, or a solvate of such a salt, whereinR.sup.1 represents a group of formula ##STR2## where R.sup.3 represents methyl or the group (CH.sub.2).sub.2 CONR.sup.4 R.sup.5 in which R.sup.4 and R.sup.5 both represent ethyl groups;R.sup.2 represents a hydrogen atom or, when R.sup.1 is the group --C(.dbd.CHNO.sub.2)NHCH.sub.3, R.sup.2 may also represent a methyl group; andn is 3 and X is oxygen, or n is 2 and X is CH.sub.2 or sulphur;with the provisos that(i) when R.sup.1 represents ##STR3## then X is sulphur and n is 2: (ii) when R.sup.1 represents --C(.dbd.CHNO.sub.2)NHCH.sub.3 and R.sup.2 is hydrogen, then X is oxygen and n is 3 or X is CH.sub.2 and n is 2; and(iii) when R.sup.1 represents --C(.dbd.CHNO.sub.2)NHCH.sub.3 and R.sup.2 is methyl, then X is oxygen and n is 3 or X is sulphur and n is 2.

Abstract: The invention relates to salts formed between basic H.sub.2 -receptor antagonists and a complex of zinc with a carboxylic acid selected from tartaric acid, citric acid and alkyl citric acids, and to solvates of such salts, excluding salts in which the basic H.sub.2 -receptor antagonist is ranitidine. Examples of basic H.sub.2 -receptor antagonists are cimetidine, famotidine, nizatidine and roxatidine.The salts are useful in the treatment of gastrointestinal disorders, such as peptic ulcer disease and non-ulcer dyspepsia.

Abstract: A process is described for the preparation of compounds of the formula ##STR1## in which W is C.sub.1-7 alkyleneX is cis or trans --CH.dbd.CH-- or --CH.sub.2 Ch.sub.2 --Y is a saturated heterocyclic amino group, andR.sup.2 is substituted or unsubstituted phenyl-, thienyl- or naphthyl-alkyl, or cinnamyl,and their salts and solvates.The process comprises hydrolysing a corresponding ester, amide, nitrile or ortho-ester. The starting materials are preferably prepared by reducing the corresponding cyclopentanone and hydrolysis can take place simultaneously with reduction.

Abstract: Compounds are described of the formula (1) ##STR1## where: R.sup.1 is a hydrogen atom or a methyl group;X is cis or trans --CH.dbd.CH-- or --CH.sub.2 CH.sub.2 --, m is 2, 3 or 4 and n is 1; or X is trans --CH.dbd.CH--, m is zero and n is 3;Y is a saturated heterocyclic amino group;Alk is a C.sub.1-5 alkyl chain;l is zero or 1;p is zero, 1, 2, 3 or 4;R.sup.2 is a hydroxyl group or a group selected from --OCOR.sup.3, --CO.sub.2 R.sup.3, CONR.sup.3 R.sup.4, --SO.sub.2 NR.sup.3 R.sup.4, --NHCOR.sup.3, --NHSO.sub.2 R.sup.5, --SO.sub.2 R.sup.5, --SR.sup.5, --NR.sup.3 R.sup.4, --COR.sup.5, --NHCONR.sup.3 R.sup.4 and --NHCSNH.sub.2 ; and their physiologically acceptable salts, solvates and cyclodextrin complexes.These compounds inhibit blood platelet aggregation, bronchoconstriction and vasoconstriction and may be formulated for use as antithrombotic agents.

Abstract: Compounds are described of formula (1) ##STR1## in which n is 1 or 2;M is 2-5 and X is --CH.dbd.CH-- or --CH.sub.2 CH.sub.2 --, or m is 1-4 and X is --CH.dbd.C.dbd.CH--;R.sup.1 is --H, C.sub.1-6 alkyl or C.sub.7-10 phenalkyl,Y substituted or unsubstituted 3-phenoxy-2-hydroxypropyl,and their salts.These compounds inhibit gastric acid secretion and provide gastrointestinal cytoprotection, and may be formulated for use in the treatment of ulcers.

Abstract: Compounds are described of the formula ##STR1## in which R.sup.1 is H, C.sub.1-6 alkyl or C.sub.7-10 aralkyl;W is C.sub.1-7 alkylene;X is cis or trans --CH.dbd.CH-- or --CH.sub.2 CH.sub.2 --;n is 1 or 2;Y is a saturated heterocyclic amino group having 5-8 ring members;R.sup.2 is (i) substituted or unsubstituted phenylalkyl, thienylalkyl or naphthylalkyl or (ii) substituted or unsubstituted cinnamyl; and their salts and solvates.These compounds inhibit blood platelet aggregation and bronchoconstriction and may be formulated for use as antithrombotic and antiasthmatic agents.

Abstract: The use is described of both (i) a systemic non-steroidal anti-inflammatory drug and (ii) a compound of formula (1) ##STR1## wherein n is 1 or 2;m is 2-5 and X is cis or trans --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --; or m is 1-4 and X is --CH.dbd.C.dbd.CH--;R.sup.1 is phenyl, substituted phenyl or naphthyl;Y is substituted or unsubstituted 3-phenoxy-2-hydroxypropyl in the therapy or prophylaxis of inflammatory conditions and for analgesia in humans.Pharmaceutical compositions containing both (i) and (ii) are also described.

Abstract: Compounds of the general formula (1) ##STR1## in which n is 1 or 2;m is 2-5 and X is --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --; or m is 1-4 and X is --CH.dbd.C.dbd.CH--;R.sup.1 is phenyl, substituted phenyl or naphthyl;Y is substituted or unsubstituted 3-phenoxy-2-hydroxypropyl.These compounds inhibit gastric acid secretion and provide gastrointestinal cytoprotection, and may be formulated for use in the treatment of ulcers.